Combination treatment of Belantamab Mafodotin and Venetoclax in treatment of relapsed and refractory t(11;14) Multiple Myeloma (Phase I/IIa) _ The BELI(E)VE-Trial

Status

Recruiting

Phases

Phase 1Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-511794-30-00

Acronym

The BELI(E)VE-Trial

Enrollment

Registered

2024-10-18

Start date

2023-06-28

Completion date

Unknown

Last updated

2025-12-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Myeloma

None listed

Sex/Gender

All

Age

18 Years to No maximum

Germany

None listed

Source: EU CTIS · Data processed: Feb 4, 2026